News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
363,179 Results
Type
Article (24471)
Company Profile (341)
Press Release (338367)
Section
Business (103913)
Career Advice (891)
Deals (17527)
Drug Delivery (41)
Drug Development (67656)
Employer Resources (76)
FDA (8999)
Job Trends (7862)
News (195045)
Policy (16053)
Tag
Academia (1547)
Alliances (28328)
Alzheimer's disease (896)
Antibody-drug conjugate (ADC) (72)
Approvals (8940)
Artificial intelligence (90)
Bankruptcy (147)
Best Places to Work (6819)
Biotechnology (282)
Breast cancer (112)
Cancer (1059)
Cardiovascular disease (77)
Career advice (733)
CAR-T (77)
Cell therapy (218)
Clinical research (53766)
Collaboration (305)
Compensation (133)
COVID-19 (2023)
C-suite (80)
Cystic fibrosis (72)
Data (998)
Diabetes (99)
Diagnostics (2824)
Earnings (38704)
Employer resources (69)
Events (62421)
Executive appointments (226)
FDA (9382)
Funding (283)
Gene therapy (160)
GLP-1 (426)
Government (2207)
Healthcare (10011)
Infectious disease (2095)
Inflammatory bowel disease (108)
Interviews (169)
IPO (9171)
Job creations (1386)
Job search strategy (633)
Layoffs (278)
Legal (2243)
Lung cancer (176)
Manufacturing (100)
Medical device (3912)
Medtech (3913)
Mergers & acquisitions (8463)
Metabolic disorders (283)
Neuroscience (1131)
NextGen Class of 2024 (2931)
Non-profit (1672)
Northern California (1157)
Obesity (150)
Opinion (140)
Parkinson's disease (67)
Patents (68)
People (31239)
Phase I (17718)
Phase II (24091)
Phase III (17265)
Pipeline (392)
Postmarket research (1584)
Preclinical (7209)
Radiopharmaceuticals (241)
Rare diseases (193)
Real estate (2144)
Regulatory (12531)
Research institute (1664)
Resumes & cover letters (147)
Southern California (1024)
Startups (2291)
United States (9582)
Vaccines (507)
Weight loss (96)
Date
Today (59)
Last 7 days (526)
Last 30 days (2821)
Last 365 days (26254)
2024 (24064)
2023 (28809)
2022 (34818)
2021 (36553)
2020 (32002)
2019 (23488)
2018 (17356)
2017 (19288)
2016 (17567)
2015 (20650)
2014 (15111)
2013 (11171)
2012 (11513)
2011 (11392)
2010 (10707)
Location
Africa (349)
Asia (22968)
Australia (4110)
California (2600)
Canada (843)
China (201)
Colorado (103)
Connecticut (107)
Europe (51720)
Florida (323)
Georgia (74)
Illinois (169)
Indiana (112)
Maryland (383)
Massachusetts (2096)
Minnesota (121)
New Jersey (729)
New York (766)
North Carolina (480)
Northern California (1157)
Ohio (96)
Pennsylvania (499)
South America (452)
Southern California (1024)
Texas (317)
Washington State (269)
363,179 Results for "immune onc therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Immune-Onc Therapeutics Announces Presentation of IO-202 Phase 1b Interim Data of Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) today announced the company will present Phase 1b interim data for IO-202 in patients with chronic myelomonocytic leukemia (CMML) at the 2024 European Hematology Association (EHA) Annual Meeting held virtually and in Madrid, Spain, June 13 – 16.
May 14, 2024
·
5 min read
Drug Development
Immune-Onc Therapeutics to Present Additional Positive Interim Data from IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress
Immune-Onc Therapeutics, Inc. announced the company will present additional positive interim Phase 1b expansion cohort data for IO-202 in patients with chronic myelomonocytic leukemia at the 2024 European Hematology Association Annual Meeting held virtually and in Madrid, Spain, June 13 – 16.
June 14, 2024
·
6 min read
Biotech Bay
Immune-Onc Therapeutics Announces Orphan Drug Designation Granted by US FDA for IO-202 (Anti-LILRB4) for the Treatment of Chronic Myelomonocytic Leukemia (CMML)
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for IO-202 for the treatment of chronic myelomonocytic leukemia (CMML).
February 21, 2024
·
6 min read
Drug Development
Immune-Onc Therapeutics Announces Clinical Trial Collaboration to Evaluate IO-108 in a Randomized Global Phase 1b/2 Study for First-Line Treatment of Advanced Liver Cancer
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) today announced a Phase 1b/2 clinical trial collaboration with Roche to evaluate Immune-Onc’s IO-108, a first-in-class antibody targeting LILRB2 (also known as ILT4), in combination with Roche’s atezolizumab and bevacizumab for the first-line treatment of patients with locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC).
February 20, 2024
·
6 min read
Diabetes
Lilly Continues Once-Weekly Insulin Rally With Two Phase III Diabetes Readouts
The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for patients with type 1 and 2 diabetes, respectively.
September 11, 2024
·
2 min read
·
Tristan Manalac
Press Releases
OncoC4 Announces First Patient Dosed in Phase 1 Trial for Novel SIGLEC10 Immune Checkpoint Inhibitor ONC-841 for Solid Tumors
September 5, 2024
·
5 min read
BioCapital
OncoC4 Announces FDA Clearance of IND Application for Novel SIGLEC 10 Immune Checkpoint Inhibitor ONC-841 for Solid Tumors
OncoC4, Inc today announced that the United States Food and Drug Administration (“FDA”) has cleared the investigational new drug (“IND”) application for ONC-841, a potential first-in-class SIGLEC 10 blocking antibody for the treatment of solid tumors.
April 23, 2024
·
2 min read
Obesity
Pfizer’s Once-Daily Weight Loss Pill—Good Play or Bad?
After nixing a twice-daily version of its oral GLP-1 agonist, Pfizer is hoping to break into the weight-loss space with a once-daily version, but experts question its outlook.
July 17, 2024
·
4 min read
·
Tyler Patchen
Genetown
Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline
Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M.
April 3, 2024
·
4 min read
Drug Development
Immune-Onc Therapeutics to Present Encouraging Phase 1 Data for IO-108 at AACR Annual Meeting 2023
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced encouraging Phase 1 dose escalation data for IO-108, a novel myeloid checkpoint inhibitor targeting Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2, also known as ILT4).
April 14, 2023
·
7 min read
1 of 36,318
Next